DxVx plans to In-License OVM-200 (Oncology Vaccine) from Oxford Vacmedix (OVM) for Asia
Shots:
- OVM has announced positive P-Ia results of OVM-200 in H1’23 and published the rationale and preclinical results of a monotx and combination study in Advanced Therapeutics comprehensively reviews
- A P-Ib trial is expected to be initiated by OVM in UK and P-Ib/II by DxVx in Asia (incl. China, Korea & India). DxVx plans to take accelerate approval pathway and estimated launch in 2027
- OVM-200 is considered safe as it is a peptide vaccine. Vaccines based on mRNA or viral particles developed using OVM's Recombinant Overlapping Peptides (ROP) platform technology. OVM is a spin-off company from Oxford University (UK) where DxVx has highest 43% stake.
Ref: PR Newswire | Image: DxVx
Related News:- CARsgen and Moderna Collaborate to Evaluate CT041 + mRNA Cancer Vaccine
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
